Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2014, Article ID 232167, 6 pages
http://dx.doi.org/10.1155/2014/232167
Research Article

Adipokines NUCB2/Nesfatin-1 and Visfatin as Novel Inflammatory Factors in Chronic Obstructive Pulmonary Disease

1Department of Respiratory Medicine, Tampere University Hospital, PL 2000, 33521 Tampere, Finland
2The Immunopharmacology Research Group, School of Medicine, University of Tampere and Tampere University Hospital, 33014 Tampere, Finland
3Allergy Centre, Tampere University Hospital, PL 2000, 33521 Tampere, Finland
4Medical Imaging Centre, Tampere University Hospital, PL 2000, 33521 Tampere, Finland
5Department of Respiratory Medicine, Seinäjoki Central Hospital, 60220 Seinäjoki, Finland

Received 13 February 2014; Revised 22 April 2014; Accepted 22 April 2014; Published 6 May 2014

Academic Editor: Vera L. Petricevich

Copyright © 2014 Sirpa Leivo-Korpela et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. “Global initiative for chronic obstructive lung disease, global strategy for the diagnosis, management and prevention of COPD,” 2013, http://www.goldcopd.org/.
  2. A. Agustí, “Systemic effects of chronic obstructive pulmonary disease: What we know and what we don't know (but should),” Proceedings of the American Thoracic Society, vol. 4, no. 7, pp. 522–525, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. P. J. Barnes and B. R. Celli, “Systemic manifestations and comorbidities of COPD,” European Respiratory Journal, vol. 33, no. 5, pp. 1165–1185, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. E. F. Wouters, N. L. Reynaert, M. A. Dentener, and J. H. Vernooy, “Systemic and local inflammation in asthma and chronic obstructive pulmonary disease is there a connection?” Proceedings of the American Thoracic Society, vol. 6, no. 8, pp. 638–647, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. N. J. Sinden and R. A. Stockley, “Systemic inflammation and comorbidity in COPD: a result of“overspill” of inflammatory mediators from the lungs? Review of the evidence,” Thorax, vol. 65, no. 10, pp. 930–936, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Fantuzzi, “Adipose tissue, adipokines, and inflammation,” Journal of Allergy and Clinical Immunology, vol. 115, no. 5, pp. 911–920, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Ouchi, J. L. Parker, J. J. Lugus, and K. Walsh, “Adipokines in inflammation and metabolic disease,” Nature Reviews Immunology, vol. 11, no. 2, pp. 85–97, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. N. Ali Assad and A. Sood, “Leptin, adiponectin and pulmonary diseases,” Biochimie, vol. 94, no. 10, pp. 2180–2189, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Oh-I, H. Shimizu, T. Satoh et al., “Identification of nesfatin-1 as a satiety molecule in the hypothalamus,” Nature, vol. 443, no. 7112, pp. 709–712, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Ramanjaneya, J. Chen, J. E. Brown et al., “Identification of nesfatin-1 in human and murine adipose tissue: a novel depot-specific adipokine with increased levels in obesity,” Endocrinology, vol. 151, no. 7, pp. 3169–3180, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. C. H. Tang, X. J. Fu, X. L. Xu, X. J. Wei, and H. S. Pan, “The anti-inflammatory and anti-apoptotic effects of nesfatin-1 in the traumatic rat brain,” Peptides, vol. 36, no. 1, pp. 39–45, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Angelone, E. Filice, T. Pasqua et al., “Nesfatin-1 as a novel cardiac peptide: identification, functional characterization, and protection against ischemia/reperfusion injury,” Cellular & Molecular Life Sciences, vol. 70, no. 3, pp. 495–509, 2013. View at Google Scholar
  13. H. Cetinkaya, B. Karagoz, O. Bilgi et al., “Nesfatin-1 in advanced lung cancer patients with weight loss,” Regulatory Peptides, vol. 181, pp. 1–3, 2013. View at Google Scholar
  14. R. I. Cohen, N. Ginsberg, D. Tsang, L. C. Wann, X. Ye, and S. F. Liu, “Association of nesfatin-1 and fat mass in cystic fibrosis,” Respiration, vol. 86, no. 4, pp. 312–317, 2013. View at Google Scholar
  15. B. Samal, Y. Sun, G. Stearns, C. Xie, S. Suggs, and I. McNiece, “Cloning and characterization of the cDNA encoding a novel human pre-B- cell colony-enhancing factor,” Molecular & Cellular Biology, vol. 14, no. 2, pp. 1431–1437, 1994. View at Google Scholar · View at Scopus
  16. E. Adeghate, “Visfatin: structure, function and relation to diabetes mellitus and other dysfunctions,” Current Medicinal Chemistry, vol. 15, no. 18, pp. 1851–1862, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Liu, H. Li, J. Cepeda et al., “Critical role of PBEF expression in pulmonary cell inflammation and permeability,” Cell Biology International, vol. 33, no. 1, pp. 19–30, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Ognjanovic and G. D. Bryant-Greenwood, “Pre-B-cell colony-enhancing factor, a novel cytokine of human fetal membranes,” The American Journal of Obstetrics and Gynecology, vol. 187, no. 4, pp. 1051–1058, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Iqbal and M. Zaidi, “TNF regulates cellular NAD+ metabolism in primary macrophages,” Biochemical and Biophysical Research Communications, vol. 342, no. 4, pp. 1312–1318, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. D. Friebe, M. Neef, J. Kratzsch et al., “Leucocytes are a major source of circulating nicotinamide phosphoribosyltransferase (NAMPT)/pre-B cell colony (PBEF)/visfatin linking obesity and inflammation in humans,” Diabetologia, vol. 54, no. 5, pp. 1200–1211, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. C. A. Curat, V. Wegner, C. Sengenès et al., “Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin,” Diabetologia, vol. 49, no. 4, pp. 744–747, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. A. R. Moschen, A. Kaser, B. Enrich et al., “Visfatin, an adipocytokine with proinflammatory and immunomodulating properties,” Journal of Immunology, vol. 178, no. 3, pp. 1748–1758, 2007. View at Google Scholar · View at Scopus
  23. T. Luk, Z. Malam, and J. C. Marshall, “Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity,” Journal of Leukocyte Biology, vol. 83, no. 4, pp. 804–816, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Q. Ye, B. A. Simon, J. P. Maloney et al., “Pre-B-cell colony-enhancing factor as a potential novel biomarker in acute lung injury,” The American Journal of Respiratory and Critical Care Medicine, vol. 171, no. 4, pp. 361–370, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. W. Gao, Q. Mao, A. W. Feng et al., “Inhibition of pre-B cell colony-enhancing factor attenuates inflammation and apoptosis induced by pandemic H1N1 2009 in lung endothelium,” Respiratory Physiology and Neurobiology, vol. 178, no. 2, pp. 235–241, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. L. Lehtimäki, H. Kankaanranta, S. Saarelainen et al., “Bronchial nitric oxide is related to symptom relief during fluticasone treatment in COPD,” European Respiratory Journal, vol. 35, no. 1, pp. 72–78, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Leivo-Korpela, L. Lehtimäki, K. Vuolteenaho et al., “Adiponectin is associated with dynamic hyperinflation and a favourable response to inhaled glucocorticoids in patients with COPD,” Respiratory Medicine, vol. 108, no. 1, pp. 122–128, 2014. View at Google Scholar
  28. H. Tilg and A. R. Moschen, “Adipocytokines: mediators linking adipose tissue, inflammation and immunity,” Nature Reviews Immunology, vol. 6, no. 10, pp. 772–783, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Conde, M. Scotece, R. Gómez et al., “Adipokines: Biofactors from white adipose tissue. A complex hub among inflammation, metabolism, and immunity,” BioFactors, vol. 37, no. 6, pp. 413–420, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Sood, “Obesity, adipokines, and lung disease,” Journal of Applied Physiology, vol. 108, no. 3, pp. 744–753, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Scotece, J. Conde, K. Vuolteenaho et al., “Adipokines as drug targets in joint and bone disease,” Drug Discovery Today, vol. 19, no. 3, pp. 241–258, 2014. View at Google Scholar
  32. P. J. Barnes, S. D. Shapiro, and R. A. Pauwels, “Chronic obstructive pulmonary disease: molecular and cellular mechanisms,” European Respiratory Journal, vol. 22, no. 4, pp. 672–688, 2003. View at Google Scholar · View at Scopus
  33. F. Bazzoni, M. A. Cassatella, F. Rossi, M. Ceska, B. Dewald, and M. Baggiolini, “Phagocytosing neutrophils produce and release high amounts of the neutrophil-activating peptide 1/interleukin 8,” Journal of Experimental Medicine, vol. 173, no. 3, pp. 771–774, 1991. View at Google Scholar · View at Scopus
  34. K. Oki, K. Yamane, N. Kamei, H. Nojima, and N. Kohno, “Circulating visfatin level is correlated with inflammation, but not with insulin resistance,” Clinical Endocrinology, vol. 67, no. 5, pp. 796–800, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. X. Liu, Y. Ji, J. Chen, S. Li, and F. Luo, “Circulating visfatin in chronic obstructive pulmonary disease,” Nutrition, vol. 25, no. 4, pp. 373–378, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. T. Romacho, L. A. Villalobos, E. Cercas, R. Carraro, C. F. Sanchez-Ferrer, and C. Peiro, “Visfatin as a novel mediator released by inflamed human endothelial cells,” PloS ONE, vol. 8, no. 10, Article ID e78283, 2013. View at Google Scholar
  37. J. C. Hogg, “Pathophysiology of airflow limitation in chronic obstructive pulmonary disease,” The Lancet, vol. 364, no. 9435, pp. 709–721, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Eker, L. Ayaz, L. Tamer, and B. Ulubas, “Leptin, visfatin, insulin resistance, and body composition change in chronic obstructive pulmonary disease,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 70, no. 1, pp. 40–44, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. G. Derosa, E. Fogari, A. D'Angelo et al., “Adipocytokine levels in obese and non-obese subjects: an observational study.,” Inflammation, vol. 36, no. 4, pp. 914–920, 2013. View at Google Scholar
  40. M. Olszanecka-Glinianowicz, P. Kocelak, M. Nylec, J. Chudek, and B. Zahorska-Markiewicz, “Circulating visfatin level and visfatin/insulin ratio in obese women with metabolic syndrome,” Archives of Medical Science, vol. 8, no. 2, pp. 214–218, 2012. View at Google Scholar
  41. F. Koehler, W. Doehner, S. Hoernig, C. Witt, S. D. Anker, and M. John, “Anorexia in chronic obstructive pulmonary disease—association to cachexia and hormonal derangement,” International Journal of Cardiology, vol. 119, no. 1, pp. 83–89, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. S. H. Jia, Y. Li, J. Parodo et al., “Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis,” Journal of Clinical Investigation, vol. 113, no. 9, pp. 1318–1327, 2004. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Marcinkowska, K. C. Lewandowski, A. Lewiński et al., “Visfatin levels do not change after the oral glucose tolerance test and after a dexamethasone-induced increase in insulin resistance in humans,” Endokrynologia Polska, vol. 58, no. 3, pp. 188–194, 2007. View at Google Scholar · View at Scopus
  44. R. Klaasen, M. M. Herenius, C. A. Wijbrandts et al., “Treatment-specific changes in circulating adipocytokines: a comparison between tumour necrosis factor blockade and glucocorticoid treatment for rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 71, no. 9, pp. 1510–1516, 2012. View at Publisher · View at Google Scholar · View at Scopus